![PDF] HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases | Semantic Scholar PDF] HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bb4db523eb74d476a02524b225eb0835b20657d2/7-Table4-1.png)
PDF] HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases | Semantic Scholar
![PDF] HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases | Semantic Scholar PDF] HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bb4db523eb74d476a02524b225eb0835b20657d2/6-Table3-1.png)
PDF] HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases | Semantic Scholar
![No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting - Gynecologic Oncology No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting - Gynecologic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6949e9c9-91e0-41e2-a2ef-b0b738887f81/gr1.jpg)
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting - Gynecologic Oncology
![Table 2 from Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo | Semantic Scholar Table 2 from Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f50dc44db73d02a0fdaecab49c845d96479f6e8f/3-Table2-1.png)
Table 2 from Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo | Semantic Scholar
![Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas | Cancer Research Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas | Cancer Research](https://cancerres.aacrjournals.org/content/canres/65/6/2162/F2.large.jpg?width=800&height=600&carousel=1)
Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas | Cancer Research
PLOS ONE: Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
![Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy | Scientific Reports Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-88780-w/MediaObjects/41598_2021_88780_Fig1_HTML.jpg)
Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy | Scientific Reports
![HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review | Cancer Epidemiology, Biomarkers & Prevention HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review | Cancer Epidemiology, Biomarkers & Prevention](https://cebp.aacrjournals.org/content/cebp/23/11/2285/F1.large.jpg?width=800&height=600&carousel=1)
HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review | Cancer Epidemiology, Biomarkers & Prevention
![Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 - ScienceDirect Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825811009735-fx2.jpg)
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 - ScienceDirect
PLOS ONE: Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
![Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses - American Journal of Obstetrics & Gynecology Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses - American Journal of Obstetrics & Gynecology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e35e4cc8-4209-4112-8fee-57071d87dede/gr1_lrg.jpg)
Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses - American Journal of Obstetrics & Gynecology
![Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer - Park - 2012 - International Journal of Cancer - Wiley Online Library Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer - Park - 2012 - International Journal of Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/2487ea26-1e5f-4b40-9ecd-fddbb803589d/ntbl003.jpg)
Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer - Park - 2012 - International Journal of Cancer - Wiley Online Library
![Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero, - ppt video online download Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero, - ppt video online download](https://slideplayer.com/slide/6626598/23/images/3/Introduction+%28cont%E2%80%99d%29.jpg)